|
Measles
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additional correlates of protection and long-term immunity and new determinants/signatures of vaccine responsiveness such as specific CD46 and IFI44L genetic variants associated with neutralizing antibody titers after measles vaccination are under investigation.
|
30585753 |
2019 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
GOS/MV-Edm remained the infectivity in murine cells that lack CD46.
|
31533779 |
2019 |
|
Measles
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD46 expression and MV infection were inhibited by nutlin3a in primary p53-competent myeloma cells, but not in p53-deficient myeloma cells, and the latter were highly sensitive to MV infection.
|
30530776 |
2018 |
|
Measles
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Protein structure analysis further identifies positive selection in the interaction interfaces between viruses and their cellular receptors (CD4-HIV; CD46-measles, adenoviruses; CD55-picornaviruses).
|
28977405 |
2017 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study reveals common CD46 and IFI44L SNPs associated with measles-specific humoral immunity, and highlights the importance of alternative splicing/virus cellular receptor isoform usage as a mechanism explaining inter-individual variation in immune response after live measles vaccine.
|
28289848 |
2017 |
|
Measles
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MPNST cell lines were found to highly express CD46, a cellular receptor required for measles viral entry, on their cell surface.
|
25843626 |
2015 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
Signalling lymphocyte activation molecule (SLAM) has been identified as an immune cell receptor for the morbilliviruses, measles (MV), canine distemper (CDV), rinderpest and peste des petits ruminants (PPRV) viruses, while CD46 is a receptor for vaccine strains of MV.
|
25171206 |
2014 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the natural host of MV is human, mouse models expressing MV entry receptors (human CD46, CD150) and disrupting the interferon (IFN) pathways work for investigating immune responses during early MV infection in vivo.
|
24905956 |
2014 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic variation in key innate pathogen recognition receptors, such as the measles cell entry receptors CD46 and SLAM, measles attachment receptor DC-SIGN, the antiviral toll-like receptors (TLR)3, TLR7 and TLR8, and the cytosolic antiviral receptor RIG-I, may significantly affect measles IgG antibody responses.
|
22871352 |
2012 |
|
Measles
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A previously detected association of the CD46 SNP rs2724384 with measles-specific antibodies was successfully replicated in this study.
|
22086389 |
2011 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast to MV-GFP, central nervous system administration of the targeted MV-GFP-H(AA)-scEGFR virus in measles replication-permissive Ifnar(ko) CD46 transgenic mice resulted in no neurotoxicity.
|
17299404 |
2007 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously shown that attenuated vaccine strains of measles virus have potent antitumor activity against gliomas, and identified H protein mutations, which ablate recognition of the natural measles virus receptors CD46 and SLAM.
|
17178881 |
2006 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CPE is dependent on expression of viral proteins and the presence of CD46, the major cellular receptor of MV-Edm.
|
15256464 |
2004 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
Measles virus receptors: SLAM and CD46.
|
15248250 |
2004 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ifnar(ko) CD46 Ge transgenic mice, susceptible to MV infection, were used to assess central nervous system toxicity of MV-CEA.
|
12750267 |
2003 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel amino acid position in hemagglutinin glycoprotein of measles virus is responsible for hemadsorption and CD46 binding.
|
12038687 |
2002 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CD46 peptide presented in the context of CPMV is also up to 100-fold more effective than the soluble CD46 peptide at inhibiting MV infection in vitro.
|
11932408 |
2002 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transgenic animals expressing CD46, a measles virus receptor, and lacking interferon type 1 receptor gene were infected intracerebrally with MVeGFP.
|
10933705 |
2000 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results document a novel CD46 transgenic murine model where MV neuronal infection is associated with the production of infectious virus, similarly to progressive infectious measles encephalitis seen in immunocompromised patients, and provide a new means to study pathogenesis of MV infection in the CNS.
|
10627548 |
2000 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results further characterize the MV-induced encephalitis in CD46 transgenic mice and highlight similarities to MV infection of the human CNS.
|
10337919 |
1999 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
This strongly suggests that the same MV binding site on CD46 is responsible for both CD46 downregulation and MV infection.
|
10527876 |
1999 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ab cross-linking of the MV receptor, CD46, mimicked the effects of MV infection in synergizing with IL-4 to induce IgE class switching, suggesting that viral hemagglutinin is involved in this synergistic effect.
|
9973418 |
1999 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
The susceptibility of CD46 (human membrane cofactor protein) transgenic mice to measles virus (MV) infection was investigated.
|
9791016 |
1998 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
Receptor (CD46)- and replication-mediated interleukin-6 induction by measles virus in human astrocytoma cells.
|
9839649 |
1998 |
|
Measles
|
0.400 |
Biomarker
|
disease |
BEFREE |
With the identification of CD46 as a measles virus (MV) receptor, it was feasible to generate transgenic rats to overcome this problem.
|
9311889 |
1997 |